https://www.pari.com/eflow-technology-partnering/customization/ 2026-07-27T14:21:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/usability-and-adherence/ 2026-04-27T15:01:18+02:00 0.5 https://www.pari.com/eflow-technology-partnering/partner-with-us/ 2025-12-17T11:06:40+01:00 0.5 https://www.pari.com/eflow-technology-partnering/partner-with-us/thank-you-for-your-e-mail/ 2026-07-27T14:56:40+02:00 0.5 https://www.pari.com/eflow-technology-partnering/manufacturing-and-supply/ 2026-04-29T14:56:30+02:00 0.5 https://www.pari.com/eflow-technology-partnering/pari-us-patents/ 2026-04-27T14:51:58+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-and-publications/news-thursday-07-dezember-2017/ 2026-07-23T12:55:31+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-and-publications/news-tuesday-02-october-2018/ 2026-07-23T12:55:20+02:00 0.5 https://www.pari.com/eflow-technology-partnering/eflow-partnering/ 2025-10-27T08:43:18+01:00 0.5 https://www.pari.com/eflow-technology-partnering/news-and-publications/drug-delivery-to-the-lungs-ddl-conference/ 2026-07-23T12:55:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/track-record-and-pipeline/ 2026-04-27T14:44:44+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-and-publications/news-tuesday-02-october-2018-1/ 2026-07-23T12:55:42+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-and-publications/news-wednesday-28-october-2020/ 2026-07-23T12:55:56+02:00 0.5 https://www.pari.com/eflow-technology-partnering/imprint/ 2026-07-27T15:16:00+02:00 0.5 https://www.pari.com/eflow-technology-partnering/data-protection/ 2025-12-17T10:52:32+01:00 0.5 https://www.pari.com/eflow-technology-partnering/data-protection/general-privacy-policy/ 2025-12-17T10:49:02+01:00 0.5 https://www.pari.com/eflow-technology-partnering/privacy-policy-social-networks/ 2025-12-17T10:39:08+01:00 0.5 https://www.pari.com/eflow-technology-partnering/data-protection/privacy-policy-rexx-applicant-portal/ 2025-12-17T10:41:07+01:00 0.5 https://www.pari.com/eflow-technology-partnering/data-protection/privacy-policy-internet/ 2025-12-17T10:46:43+01:00 0.5 https://www.pari.com/eflow-technology-partnering/new-drug-nebulizer-combination-products/ 2026-07-27T15:00:13+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-and-publications/news-tuesday-23-march-2021/ 2026-07-23T12:56:05+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-and-publications/news-friday-25-june-2021/ 2026-07-23T12:54:48+02:00 0.5 https://www.pari.com/eflow-technology-partnering/expert-interviews/ 2026-04-27T14:39:01+02:00 0.5 https://www.pari.com/eflow-technology-partnering/search/ 2025-08-01T13:28:38+02:00 0.5 https://www.pari.com/eflow-technology-partnering/404/ 2026-07-27T15:15:20+02:00 0.5 https://www.pari.com/eflow-technology-partnering/ehealth-and-digital-solutions/ 2026-04-27T14:56:23+02:00 0.5 https://www.pari.com/eflow-technology-partnering/eflow-partnering/ 2026-07-27T14:17:51+02:00 0.5 https://www.pari.com/eflow-technology-partnering/data-protection/cookie-consent/ 2026-07-27T15:17:05+02:00 0.5 https://www.pari.com/eflow-technology-partnering/403/ 2026-07-27T15:15:44+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/ 2026-07-23T14:39:39+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/categories/ 2026-07-23T14:33:43+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-announces-the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-has-accepted-the-molbreevi-marketing-authorisation-application-maa-for-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/avalyn-completes-target-enrollment-in-phase-2b-mist-trial-of-ap01-inhaled-pirfenidone-for-patients-with-progressive-pulmonary-fibrosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-announces-the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-has-accepted-the-molbreevi-marketing-authorisation-application-maa-for-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap-1/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/insmed-announces-positive-topline-results-from-phase-3b-encore-study-of-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-mac-lung-disease/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/avalyn-announces-first-patient-dosed-in-aura-phase-2-clinical-trial-evaluating-ap02-inhaled-nintedanib-for-the-treatment-of-idiopathic-pulmonary-fibrosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-and-pari-granted-a-european-patent-covering-the-drug-device-combination-of-molbreevi-delivered-via-the-proprietary-eflowr-nebulizer-system/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/customization-is-key/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-completes-submission-of-the-biologics-license-application-bla-to-the-us-food-and-drug-administration-fda-for-molbreevi-as-a-treatment-for-autoimmune-pulmonary-alveolar-proteinosis-apap/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-announces-manuscript-on-long-term-outcomes-with-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-published-in-erj-open-research/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/a-novel-hf-user-characteristics-assessment-approach-for-a-new-platform-based-breath-triggered-nebulizer-in-inhalation-therapy/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/from-continuity-to-competitive-edge-how-long-term-collaboration-drives-hf-program-success/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/the-importance-of-mesh-nebulizer-configuration-in-mrna-lnp-delivery-performance/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/effect-of-nebulizer-breath-guiding-on-breathing-patterns/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-announces-manuscript-on-long-term-outcomes-with-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-published-in-erj-open-research-1-2/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/analysis-of-mrna-delivery-performance-via-vibrating-mesh-nebulization/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/a-novel-hf-user-characteristics-assessment-approach-for-a-new-platform-based-breath-triggered-nebulizer-in-inhalation-therapy-1/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-initiates-rolling-submission-of-a-biologics-license-application-bla-to-the-us-food-and-drug-administration-fda-for-molbreevi-for-the-potential-treatment-of-autoimmune-pulmonary-alveolar-proteinosis-apap/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-announces-molgramostim-nebulizer-solution-molgramostim-achieved-statistical-significance-for-primary-endpoint-and-multiple-secondary-endpoints-in-impala-2-a-pivotal-phase-3-clinical-trial-in-autoimmune-pulmonary-alveolar-proteinosis-apap/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/renovion-announces-positive-top-line-results-from-phase-2-climb-study-of-arina-1-rvn-301-in-patients-with-non-cystic-fibrosis-bronchiectasis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/insmed-announces-positive-topline-results-from-phase-3-arise-study-of-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-ntm-lung-disease-caused-by-mac/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-completes-enrollment-of-pivotal-phase-3-impala-2-trial-of-molgramostim-nebulizer-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/zambon-completes-enrollment-in-phase-3-clinical-development-program-evaluating-liposomal-cyclosporine-a-for-inhalation-l-csa-i-in-patients-with-bronchiolitis-obliterans-syndrome-bos/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/first-patient-enrolled-in-phase-3-clinical-trial-evaluating-arina-1-in-lung-transplant/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/avalyn-pharma-reports-results-of-phase-1-study-of-ap02-in-healthy-volunteers-and-participants-with-idiopathic-pulmonary-fibrosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/renovion-receives-fda-fast-track-designation-for-arina-1-for-the-prevention-of-bos-progression-in-lung-transplant-patients/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/avalyn-pharma-publishes-phase-1b-atlas-results-demonstrating-stabilization-of-lung-function-at-24-and-48-weeks-with-ap01-and-favorable-safety-profile/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/recode-therapeutics-announces-first-participants-dosed-in-a-phase-1-healthy-volunteer-clinical-trial-of-novel-disease-modifying-genetic-medicine-rct1100-for-the-treatment-of-primary-ciliary-dyskinesia/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/spexis-reports-solid-safety-and-pharmacokinetics-results-from-first-in-human-study-with-inhaled-murepavadin-a-novel-macrocycle-compound/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/first-patient-enrolled-in-phase-2-clinical-study-evaluating-arina-1-for-the-treatment-of-ncfbe/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-awarded-promising-innovative-medicine-pim-designation-in-the-united-kingdom-uk-for-molgramostim-nebulizer-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/renovion-receives-notice-of-study-may-proceed-status-for-lung-transplant-program/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-awarded-innovation-passport-in-united-kingdom-uk-for-molgramostim-nebulizer-solution-molgramostim-a-novel-investigational-inhaled-biologic/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/polyphor-closes-merger-with-enbiotix-and-is-renamed-spexis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/savara-announces-first-patient-dosed-in-pivotal-phase-3-autoimmune-pulmonary-alveolar-proteinosis-apap-trial/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/dr-stefan-seemann-is-appointed-president-of-pari-pharma-gmbh/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/avalyn-pharma-reports-statistically-significant-dose-response-with-aerosolized-pirfenidone-in-an-idiopathic-pulmonary-fibrosis-trial/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/insmed-presents-broad-range-of-data-across-its-three-programs-at-the-american-thoracic-society-2021-international-conference/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/key-data-on-economic-impact-of-bronchiolitis-obliterans-syndrome-bos-presented-at-ishlt-2021/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/lamirar-an-eflowr-technology-nebulizer-expected-to-launch-in-japan-as-a-medical-device-for-exclusive-administration-of-arikaycer-amikacin-liposome-inhalation-suspension/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/santhera-announces-positive-results-with-lonodelestat-in-early-phase-cystic-fibrosis-trial/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/insmed-initiates-frontline-clinical-trial-program-for-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-mac-lung-disease/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/polyphor-receives-approval-to-start-first-in-human-clinical-trial-of-inhaled-antibiotic-murepavadin/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/polyphor-receives-award-of-up-to-usd-33-million-from-cystic-fibrosis-foundation-to-support-clinical-development-of-inhaled-murepavadin/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/lamirar-an-eflowr-technology-nebulizer-is-the-only-device-to-deliver-insmeds-arikaycer-liposomal-590-mg-nebuliser-dispersion-in-the-european-union/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/paris-optimized-investigational-eflowr-technology-nebulizer-delivering-well-tolerated-aerosols-of-ar-501-in-aridis-phase-12a-clinical-trial/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/avalyn-pharma-reports-update-in-ongoing-idiopathic-pulmonary-fibrosis-trial/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/ionis-inhaled-antisense-medicine-demonstrates-potential-as-a-novel-treatment-for-cystic-fibrosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/insmed-receives-positive-chmp-opinion-for-arikayce-liposomal-590-mg-nebuliser-dispersion-for-the-treatment-of-ntm-lung-infections-caused-by-mac-in-non-cf-patients-with-limited-treatment-options/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/new-ntm-treatment-guidelines-recommend-insmeds-arikaycer-amikacin-liposome-inhalation-suspension-for-treatment-of-patients-with-refractory-mac-lung-disease/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/renovion-announces-completion-of-81-million-financing-round-enabling-clinical-programs-in-chronic-inflammatory-lung-diseases/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/biomarck-pharmaceuticals-to-present-expanded-analysis-of-bio-11006-clinical-data-in-treatment-of-non-small-cell-lung-cancer-at-the-american-thoracic-society-2020-international-conference/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/a-new-fda-fast-track-designation-for-zambon/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/breath-therapeutics-a-zambon-company-initiates-boston-3-and-boston-4-two-additional-clinical-studies-for-the-treatment-of-bronchiolitis-obliterans-syndrome-bos/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/kamada-announces-enrollment-of-first-patient-into-its-pivotal-phase-3-innovaate-clinical-trial-of-inhaled-aat-for-the-treatment-of-alpha-1-antitrypsin-deficiency/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/santhera-announces-publication-of-phase-i-clinical-data-with-pol6014-in-journal-of-cystic-fibrosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/pari-pharma-spin-out-breath-therapeutics-acquired-by-zambon-pharma/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/new-phase-3-data-show-sustainability-and-durability-of-culture-conversion-with-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-refractory-mac-lung-disease/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/sunovion-to-present-data-on-lonhalar-magnairr-inhalation-solution-and-copd-at-the-american-thoracic-society-international-conference-2019/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/breath-therapeutics-announces-initiation-of-global-phase-3-trials-for-the-treatment-of-bronchiolitis-obliterans-syndrome/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/pari-pharmas-eflowr-technology-device-lamiratm-approved-as-the-only-nebulizer-system-to-deliver-insmeds-arikaycer-amikacin-liposome-inhalation-suspension/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/magnairtm-an-eflowr-closed-system-nebulizer-together-with-sunovions-lonhalatm-is-the-first-eflow-technology-based-product-to-receive-fda-approval-to-treat-chronic-obstructive-pulmonary-disease-copd/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/eflow-integrated-aerosol-performance-of-a-novel-breath-triggered-nebulizer/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/optimising-inhalation-adherence-and-technique-the-power-of-digital-technology/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/deep-breaths-deep-dives-the-new-eflow-integrated-nebuliser/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/safety-and-efficacy-of-the-epithelial-sodium-channel-blocker-idrevloride-in-people-with-primary-ciliary-dyskinesia-clean-pcd-a-multinational-phase-2-randomised-double-blind-placebo-controlled-crossover-trial/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/large-eddy-simulation-convective-instability-and-modal-causality-of-coaxial-supersonic-air-water-jets-considering-a-swirl-effect/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/mucosal-adenoviral-vectored-vaccine-boosting-durably-prevents-xbb116-infection-in-nonhuman-primates/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/aerosol-delivery-of-sars-cov-2-human-monoclonal-antibodies-in-macaques-limits-viral-replication-and-lung-pathology/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/transient-aerosol-measurements-assessing-the-eflow-nebulizer-aerosol-bolus/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/nebulization-of-pegylated-recombinant-human-deoxyribonuclease-i-using-vibrating-membrane-nebulizers-a-technical-feasibility-study/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/inhaled-pirfenidone-solution-ap01-for-ipf-a-randomised-open-label-dose-response-trial/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/differential-performance-and-lung-deposition-of-levofloxacin-with-different-nebulisers-used-in-cystic-fibrosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/a-randomized-controlled-trial-of-liposomal-cyclosporine-a-for-inhalation-in-the-prevention-of-bronchiolitis-obliterans-syndrome-following-lung-transplantation/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/inhaled-medicines-past-present-and-future/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/unsteady-aerosol-output-rate-measurements-assessing-the-eflow-nebulizer-aerosol-bolus/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/towards-more-realistic-in-vitro-nebulizer-testing/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/development-of-a-novel-test-stand-for-the-measurement-of-valved-holding-chambers-with-facemasks/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/eflow-technology-nebulisers-with-digital-therapy-management-the-pari-connect-eco-system/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/deposition-of-inhaled-levofloxacin-in-cystic-fibrosis-lungs-assessed-by-functional-respiratory-imaging/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution-1-18/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/self-management-intervention-to-reduce-pulmonary-exacerbations-by-supporting-treatment-adherence-in-adults-with-cystic-fibrosis-a-randomised-controlled-trial/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution-1-20/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/robustness-of-aerosol-delivery-of-amikacin-liposome-inhalation-suspension-using-the-eflowr-technology/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/development-of-an-intervention-to-increase-adherence-to-nebuliser-treatment-in-adults-with-cystic-fibrosis-cfhealthhub/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/how-cold-is-cold-enough-refrigeration-of-the-next-generation-impactor-to-prevent-aerosol-undersizing/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/improvement-in-lung-function-and-patient-reported-outcomes-in-patients-with-copd-with-comorbid-anxiety-and-depression-receiving-nebulized-glycopyrrolate-in-the-golden-3-and-4-studies/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/inhaled-molgramostim-therapy-in-autoimmune-pulmonary-alveolar-proteinosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/improved-bioavailability-of-cromolyn-sodium-using-inhaled-pa101-delivered-via-eflowr-nebulizer/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/observational-real-world-study-to-assess-clinical-characteristics-and-device-satisfaction-in-patients-with-copd-treated-with-glycopyrrolateeflowr-cs/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/aerosol-pirfenidone-pharmacokinetics-after-inhaled-delivery-in-sheep-a-viable-approach-to-treating-idiopathic-pulmonary-fibrosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/making-concentrated-antibody-formulations-accessible-for-vibrating-mesh-nebulization/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/a-randomized-double-blinded-placebo-controlled-dose-escalation-phase-1-study-of-aerosolized-pirfenidone-delivered-via-the-pari-investigational-eflow-nebulizer-in-volunteers-and-patients-with-idiopathic-pulmonary-fibrosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/a-randomised-single-centre-trial-of-inhaled-liposomal-cyclosporine-for-bronchiolitis-obliterans-syndrome-post-lung-transplantation/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/single-dose-escalation-studies-with-inhaled-pol6014-a-potent-novel-selective-reversible-inhibitor-of-human-neutrophil-elastase-in-healthy-volunteers-and-subjects-with-cystic-fibrosis/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/topical-application-of-nebulized-human-igg-iga-and-igam-in-the-lungs-of-rats-and-non-human-primates/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution-1-34/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/monitoring-nebuliser-usage-lung-function-in-clinical-trials/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/monitoring-adherence-to-treatment-regimen-of-inhaled-medication-use-in-a-clinical-trial-with-an-investigational-eflow-nebulizer-etrack/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/randomized-trial-of-efficacy-and-safety-of-dornase-alfa-delivered-by-erapid-nebulizer-in-cystic-fibrosis-patients/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/in-vitro-study-of-aerosolised-colistin-delivered-to-the-nasal-tract-via-a-pulsating-aerosol-delivery-device-vibrentr/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/drug-delivery-to-paranasal-sinuses-using-pulsating-aerosols/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/the-eflow-closed-systemcs-a-novel-device-platform-for-liquid-aerosol-drug-device-combinations/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/a-pharmacokinetics-and-safety-comparison-of-a-highly-concentrated-tobramycin-solution-with-tobi/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/some-cystic-fibrosis-patients-do-not-tolerate-tobramycin-dry-powder-inhalation/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/topical-drug-delivery-in-chronic-rhinosinusitis-patients-before-and-after-sinus-surgery-using-pulsating-aerosols/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution-1-44/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/assessing-modeled-co2-retention-and-rebreathing-of-a-facemask-designed-for-efficient-delivery-of-aerosols-to-infants/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/a-comparison-of-amount-and-speed-of-deposition-between-the-pari-lc-starr-jet-nebulizer-and-an-investigational-eflowr-nebulizer/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/pulsating-aerosols-for-drug-delivery-to-the-sinuses-in-healthy-volunteers/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/lung-deposition-of-a-liposomal-cyclosporine-a-inhalation-solution-in-patients-after-lung-transplantation/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/objective-evaluation-of-adherence-to-inhaled-liposomal-cyclosporin-therapy-for-lung-transplant-patients-in-a-clinical-trial/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/nasally-inhaled-pulsating-aerosols-lung-sinus-and-nose-deposition/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/a-novel-nebuliser-for-the-simultaneous-administration-of-sirna-and-supplemental-oxygen-for-rsv-in-infants/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/new-advances-in-aerosolised-drug-delivery-vibrating-membrane-nebuliser-technology/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/the-customised-electronic-nebuliser-a-new-category-of-liquid-aerosol-drug-delivery-systems/ 2026-07-23T13:24:06+02:00 0.5 https://www.pari.com/eflow-technology-partnering/news-publications/enterprise-therapeutics-achieves-primary-efficacy-outcome-in-phase-2-clinical-trial-for-cystic-fibrosis-with-novel-inhaled-enac-blocker-etd001/ 2026-07-23T15:08:02+02:00 0.5